» Articles » PMID: 35031096

Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) Statement: Updated Reporting Guidance for Health Economic Evaluations

Abstract

Health economic evaluations are comparative analyses of alternative courses of action in terms of their costs and consequences. The Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement, published in 2013, was created to ensure health economic evaluations are identifiable, interpretable, and useful for decision making. It was intended as guidance to help authors report accurately which health interventions were being compared and in what context, how the evaluation was undertaken, what the findings were, and other details that may aid readers and reviewers in interpretation and use of the study. The new CHEERS 2022 statement replaces previous CHEERS reporting guidance. It reflects the need for guidance that can be more easily applied to all types of health economic evaluation, new methods and developments in the field, as well as the increased role of stakeholder involvement including patients and the public. It is also broadly applicable to any form of intervention intended to improve the health of individuals or the population, whether simple or complex, and without regard to context (such as health care, public health, education, social care, etc). This summary article presents the new CHEERS 2022 28-item checklist and recommendations for each item. The CHEERS 2022 statement is primarily intended for researchers reporting economic evaluations for peer reviewed journals as well as the peer reviewers and editors assessing them for publication. However, we anticipate familiarity with reporting requirements will be useful for analysts when planning studies. It may also be useful for health technology assessment bodies seeking guidance on reporting, as there is an increasing emphasis on transparency in decision making.

Citing Articles

Estimated Cancer Risk in Females Who Meet the Criteria to Exit Cervical Cancer Screening.

Kulasingam S, de Kok I, Mehta A, Jansen E, Regan M, Killen J JAMA Netw Open. 2025; 8(3):e250479.

PMID: 40072436 PMC: 11904717. DOI: 10.1001/jamanetworkopen.2025.0479.


Time-varying cost-effectiveness analysis of sodium-glucose cotransporter-2 inhibitors in Chinese patients with heart failure and reduced ejection fraction: A microsimulation of the real-world population.

Zou X, He X, Shi Q, Wang S, Li N, Zhou Y Front Pharmacol. 2025; 16:1527972.

PMID: 40070563 PMC: 11893398. DOI: 10.3389/fphar.2025.1527972.


Long-term cost-effectiveness of health behaviour intervention to manage type 2 diabetes in Nepal.

Dahal P, Vandelanotte C, Rawal L, Mahumud R, Paudel G, Lloyd M BMC Med. 2025; 23(1):153.

PMID: 40069657 PMC: 11900644. DOI: 10.1186/s12916-025-03981-8.


Health and Economic Impact of COVID-19 Surveillance Testing in Seattle Homeless Shelters: A Cost-Effectiveness Analysis.

Cox S, Chow E, Rolfes M, Mosites E, Sharma M, Chu H AJPM Focus. 2025; 4(2):100307.

PMID: 40061153 PMC: 11889550. DOI: 10.1016/j.focus.2024.100307.


Cost-effectiveness of atezolizumab plus bevacizumab versus sorafenib as first-line therapy in unresectable hepatocellular carcinoma in the US and Chinese setting: a modelling comparison study.

Liu L, Wang L, Ding Y, Zhang Q, Shu Y BMJ Open. 2025; 15(3):e094804.

PMID: 40050065 PMC: 11887288. DOI: 10.1136/bmjopen-2024-094804.